Executive Director, HTA Strategy, Europe

Confirmed live in the last 24 hours

Revolution Medicines

Basel, Basel-Stadt, Switzerland

Remote

Posted April 10, 2026

Job Description

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway.

The Opportunity:

The Executive Director, Health Technology Assessment (HTA) Strategy will lead the end-to-end execution of EU Joint Clinical Assessments (JCA) and Joint Scientific Consultations (JSC) across Revolution Medicines' oncology portfolio but not limited to JCA governance, timely submission delivery, and post-JCA coordination with European operating countries, enable efficient national HTA and payer submissions aligned with EMA timelines. In addition, this role will partner closely with HEOR, Medical, Commercial, Global Market Access, Clinical Development, Biostatistics, Regulatory, and local operating country teams.

Key Responsibilities

EU JCA Leadership & Governance

Serve as the single accountable European leader for EU JCA execution across oncology programs, ensuring high-quality, on-time submissions.
Establish and lead JCA governance, including cross-functional teams, Member State input mechanisms, and escalation pathways.
Own EMA–JCA timeline integration, ensuring dossier readiness aligned to regulatory and HTA milestones.
Lead or support Joint Scientific Consultations (JSC) to collect early HTA feedback on clinical trial design and evidence generation strategy.

JCA Scoping, PICO Projection & Evidence Package Coordination

Lead coordination of JCA scoping and PICO projection, incorporating Member State input and resolving execution implications.
Translate PICO requirements into clear evidence and dossier execution plans, in partnership with HEOR, Clinical Development, and Biostatistics.
Coordinate delivery and positioning of: comparative clinical effectiveness and safety evidence; subgroup, sensitivity, and maturity analyses; indirect treatment comparisons, where required.

Cross-Functional Coordination

Partner with Biostatistics leadership to ensure JCA-relevant analyses are prioritized and delivered within required timelines.
Oversee cross-functional interpretation of analytical outputs to ensure consistency, traceability, and HTA-appropriate framing.
Lead responses to HTA assessor questions, including requests for clarification or additional analyses.
Collaborate with global and regional cross-functional teams to contribute to the strategy and projects impacting and enabling JCA dossiers and evaluations.

JCA Dossier Development & Submission

Own the end-to-end JCA dossier, including content orchestration, review cycles, submission management, and quality control.
Lead interactions related to completeness checks, assessor questions, and factual accuracy reviews.

External Engagement & Vendor Management

Lead or support scientific advice interactions with EU HTA bodies as relevant to JCA positioning.
Build working relationships with assessor and co-assessor Member State HTA agencies to anticipate requirements and resolve issues proactively.
Manage external partners and vendors supporting JCA dossier development and submission logistics.

Post-JCA Country & Global Deployment

goaiiosdatadesign